

The AI Revolution in Medicine: Predicting, Preventing, and Curing Diseases with Artificial Intelligence

Revolusi AI dalam Kedokteran: Memprediksi, Mencegah, dan Menyembuhkan Penyakit dengan Kecerdasan Buatan

Joaquim Pinto

Universidade Nacional Timor Loro Sa'e

*pintotio123@gmail.com

**Corresponding Author*

ABSTRACT

This research aims to explore the use of artificial intelligence (AI) in disease risk prediction and disease prevention through a systematic review of literature from 2019 to 2024. The research method used is an analysis of scientific articles published in international journals Scopus Q1. The research results show a significant increase in the use of AI in disease risk prediction, especially in the context of neurodegenerative diseases, cardiovascular conditions, cancer, and autoimmune diseases. The implications of this research include the potential of AI in improving the accuracy of disease risk predictions, providing timely interventions, and improving the clinical management of patients. However, the use of AI in disease risk prediction is also faced with various ethical challenges and impacts, including limited available health data, the complexity of AI models, complex interpretation of results, and privacy and fairness issues. The practical implication of this research is the need for a holistic and sustainable approach in the development and implementation of AI models in disease prevention, which takes into account the complex challenges and opportunities associated with the use of AI in health contexts.

Keywords: Artificial Intelligence, Disease Risk Prediction, Disease Prevention, Systematic Review, Medical Literature, Challenges, Ethical Impact

ABSTRAK

Penelitian ini bertujuan untuk mengeksplorasi penggunaan kecerdasan buatan (AI) dalam prediksi risiko penyakit dan pencegahan penyakit melalui tinjauan sistematis literatur dari tahun 2019 hingga 2024. Metode penelitian yang digunakan adalah analisis terhadap artikel-artikel ilmiah yang diterbitkan di jurnal-jurnal internasional Scopus Q1. Hasil penelitian menunjukkan peningkatan signifikan dalam penggunaan AI dalam prediksi risiko penyakit, terutama dalam konteks neurodegenerative diseases, cardiovascular conditions, cancer, dan autoimmune diseases. Implikasi penelitian ini mencakup potensi AI dalam meningkatkan akurasi prediksi risiko penyakit, memberikan intervensi yang tepat waktu, dan meningkatkan manajemen klinis pasien. Meskipun demikian, penggunaan AI dalam prediksi risiko penyakit juga dihadapkan pada berbagai tantangan dan dampak etis, termasuk keterbatasan data kesehatan yang tersedia, kompleksitas model AI, interpretasi hasil yang rumit, serta masalah privasi dan keadilan. Implikasi praktis dari penelitian ini adalah perlunya pendekatan holistik dan berkelanjutan dalam pengembangan dan implementasi model AI dalam pencegahan penyakit, yang memperhatikan tantangan yang kompleks dan peluang yang terkait dengan penggunaan AI dalam konteks kesehatan.

Kata Kunci: Kecerdasan Buatan, Prediksi Risiko Penyakit, Pencegahan Penyakit, Tinjauan Sistematis, Literatur Medis, Tantangan, Dampak Etis

1. Introduction

The integration of artificial intelligence (AI) in the field of medicine has sparked a revolution, offering the potential to predict, prevent, and cure diseases. AI, through algorithms and predictive models, has shown promise in diagnosing diseases, predicting therapeutic responses, and enabling personalized medicine (Kumar et al., 2022). This has generated

enthusiasm in the medical field, as AI has the potential to assist physicians in establishing diagnoses, predicting the risk of diseases, and facilitating drug discovery (Diaconu et al., 2022). Furthermore, AI is driving a transformation in healthcare, enabling a shift towards proactive and personalized medicine, aligning with the concept of P5 medicine – predictive, personalized, preventive, participatory, and precision-focused discipline (Denecke & Baudoin, 2022).

The use of AI in disease diagnosis has been assessed through various strategies such as Logit Boost, Bayesian Network Classifier, Support Vector Machine, and Random Tree Forest, showing potential in identifying conditions like hypertension (Kumar et al., 2022). However, the adoption of AI in the healthcare system and medical education is a rapidly growing area, emphasizing the importance of involving healthcare professionals and educators in the development and implementation of AI-enabled tools in medicine (Iqbal, 2022). Additionally, AI algorithms, including data-driven, image-driven, natural language processing (NLP)-driven, genomics-driven, and multimodality algorithms, have been instrumental in improving disease detection and outcomes (Lim et al., 2022).

While AI presents significant potential, there are also challenges to address. The application of AI in medicine raises concerns regarding bias and clinical safety, as machine learning techniques are increasingly applied to complex problems, allowing computers to make predictions from large amounts of patient data (Challen et al., 2019). Moreover, the implementation of AI in the practice of medicine requires meeting specific requirements, and unlike other medical imaging areas, no histopathology-based AI application has been approved for public reimbursement (Yoshida & Kiyuna, 2021).

In the context of the COVID-19 pandemic, modern technologies, including AI, have been pivotal in disease tracking, prediction outcomes, and computational biology, highlighting the diverse applications of AI in addressing public health crises (Kumar et al., 2020). Furthermore, the understanding of causality within data, facilitated by causal inference, has been identified as a significant component of AI, promoting human understanding of the learning process and model prediction (Ma & Li, 2022).

In conclusion, the integration of AI in medicine holds immense potential for revolutionizing disease diagnosis, prediction, prevention, and personalized medicine. However, it is essential to address challenges such as bias, clinical safety, and regulatory approval to fully harness the benefits of AI in transforming healthcare.

Artificial intelligence (AI) has emerged as a transformative tool in healthcare, particularly in disease risk prediction and prevention. Recent studies have highlighted the potential of AI in providing cardiovascular disease prevention recommendations (Sarraj et al., 2023). The integration of AI with precision medicine has shown promise in personalized health care, emphasizing the importance of risk assessment and patient-specific modeling (Johnson et al., 2020). Furthermore, systematic reviews have demonstrated the expanding role of AI applications in real-life clinical practice, emphasizing its significance in modern medicine (Yin et al., 2021). The advancements in AI software and hardware, particularly deep learning algorithms, have led to a surge in medical AI applications, especially in clinical and genomic diagnostics (Dias & Torkamani, 2019). In the context of chronic disease management, AI has been identified as a key enabler of precision medicine, offering implications for improving patient outcomes (Mahadevan et al., 2020). Additionally, AI has been utilized to identify genetic susceptibility to diseases such as atrial fibrillation through deep learning of electrocardiograms, showcasing its potential in disease risk estimation (Wang, 2023). Moreover, the integration of AI with neuroimaging has raised exciting promises for personalized prevention and treatment in Alzheimer's disease (Mirkin & Albensi, 2023). The review of AI and robotics in transformed health ecosystems has emphasized the proactive nature of healthcare, aligning with the concept of predictive, personalized, preventive, participatory, and precision medicine (P5 medicine) (Denecke & Baudoin, 2022). Furthermore, ongoing research is exploring the potential of AI applications in decision-making for disease

management, indicating a growing interest in leveraging AI for improving clinical practice and health outcomes (Abdekhoda & Ranjbaran, 2023).

In conclusion, the synthesis of these references underscores the significant role of AI in estimating disease risk and its occurrence. The integration of AI with precision medicine, clinical practice, and decision-making processes holds immense potential for advancing healthcare and fostering personalized, preventive interventions.

2. Research Methods

In this research, the method used is a systematic literature review. The first step in the research method is collecting articles from reputable international databases. Databases used included PubMed, Web of Science, and Scopus, to ensure comprehensive literature coverage. The search keywords used included terms such as "artificial intelligence", "medicine", "prediction", "prevention", "disease", and other variations. The search process uses a combination of these keywords to obtain relevant articles. Once the search process was complete, the number of articles retrieved was evaluated to ensure adequate coverage in the study.

Furthermore, in the article inclusion and exclusion technique, strict criteria are applied to select articles that suit the research objectives. Relevant articles were selected based on inclusion criteria that included a focus on the application of artificial intelligence in disease prediction and prevention, as well as publications in peer-reviewed scientific journals. Articles that do not meet the inclusion criteria or are not directly relevant to the research topic will be excluded from this study.

Finally, this study adopted the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) method in compiling and reporting this literature review. The PRISMA method provides a structured framework for conducting a systematic literature review by following clear steps, including identification, selection, assessment, and synthesis of articles. By using the PRISMA method, this research is expected to provide a clear, transparent and systematic report on literature findings related to the application of artificial intelligence in estimating disease risk and preventing it.

3. Results and Discussions

3.1.1. Disease Prediction with Artificial Intelligence

Artificial intelligence (AI) has been increasingly utilized in the field of medicine for disease prediction and diagnosis (Beheshti et al., 2023). highlighted the advanced AI methods for applications in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, to enhance the understanding of these conditions (Beheshti et al., 2023). Similarly, emphasized the potential of AI through algorithms and predictive models to diagnose diseases and predict therapeutic responses (Al-Shoteri, 2022). Furthermore, Stafford et al. (2020) conducted a systematic review on the applications of AI and machine learning in autoimmune diseases, aiming to improve patient care (Stafford et al., 2020). These references collectively underscore the growing significance of AI in disease prediction and diagnosis.

In the context of specific diseases, Mohan et al. (2019) demonstrated the effectiveness of AI, particularly Artificial Neural Network (ANN), in predicting heart disease, indicating the potential for AI to contribute to the early detection and management of cardiovascular conditions (Mohan et al., 2019). Additionally, Almansour (2022) discussed the role of AI in the efficient diagnosis and management of triple-negative breast cancer, highlighting the power of AI in different scientific fields, particularly in medicine (Almansour, 2022). Moreover, Zhang et al. (2020) identified immune genes as prognostic biomarkers for breast cancer through the application of AI algorithms, signifying the potential for AI to contribute to personalized mortality risk prediction for cancer patients (Zhang et al., 2020).

Furthermore, the integration of AI with medical imaging has shown promise in assisting

with tumor and cardiovascular disease diagnosis, as indicated by (Mascarenhas et al., 2021). Additionally, Sahu & Kumar (2022) discussed the application of AI in predictive analysis for the detection of various human diseases, including cardiovascular disease and chronic kidney disease, using supervised and ensemble machine learning classification algorithms, highlighting the potential for AI to contribute to early disease detection and intervention (Sahu & Kumar, 2022).

In conclusion, the references from 2019-2024 collectively demonstrate the increasing utilization of AI in disease prediction and diagnosis, particularly in the context of neurodegenerative diseases, cardiovascular conditions, cancer, and autoimmune diseases. These studies underscore the potential for AI to revolutionize the field of medicine by enabling early detection, personalized risk prediction, and improved clinical management of various diseases.

The use of artificial intelligence (AI) in predicting disease risk has gained significant attention in modern medical research. Machine learning algorithms, including logistic regression, artificial neural networks, and decision trees, have been widely employed to utilize clinical and biomedical data for disease risk prediction (Liu, 2024). These methods offer the potential to identify biomarkers and predict the risk of severe diseases, such as SARS-CoV-2 infection, in individuals (Liu, 2024). However, the success of AI in disease risk prediction is evaluated based on criteria such as prediction accuracy, sensitivity, and specificity, while challenges such as data limitations, model complexity, and result interpretation problems also need to be carefully considered (Liu, 2024). The decision tree algorithm, for instance, has been widely used in disease risk prediction, early warning, and prognosis, demonstrating the diverse methods employed in clinical practice (Li & Chong-Wen, 2022). Furthermore, the application of machine learning algorithms in medical research has shown promise in predicting diseases such as heart disease, diabetes, Parkinson's disease, and gestational diabetes mellitus, among others. These algorithms have been utilized to improve patient outcomes, reduce healthcare costs, and enable personalized medicine (Siddiq, 2022). However, the challenges faced in disease prediction, such as the imbalanced class problem in measles infection risk prediction, highlight the need for careful evaluation and understanding of the limitations of AI in a medical context (Ahmad et al., 2019). Therefore, comprehensive insight into the role of AI in predicting disease risk requires a deep understanding of the successes and challenges faced, emphasizing the significance of this research in contributing to our understanding of the potential and limitations of AI in a medical context (Liu, 2024).

3.2. Discussion of the Advantages and Limitations of the Approach Used

3.2.1. Advantages of the AI Approach in Predicting Disease Risk

The use of artificial intelligence (AI) in predicting disease risk offers several advantages in healthcare. AI-based risk scores have the potential to enhance the accuracy of predicting patients at higher risk, facilitating timely intervention and resource allocation (Barbieri, 2024). Particularly, the application of AI/ML for detecting infectious diseases in high-risk populations, where mortality remains high, has significant appeal (Tran et al., 2023). AI in medicine has rapidly increased with respect to tasks including disease detection/diagnosis, risk stratification, and prognosis prediction, offering a data-driven and hypothesis-free approach that better incorporates clinical factors to detect hidden patterns for disease detection/prediction (Chen et al., 2021; Wong et al., 2021). Furthermore, AI can impact future patient care and address potential challenges, reducing the workload of doctors (Vaishya et al., 2020). In addition, AI in healthcare is becoming increasingly essential due to its potential to enhance clinical risk predictions and advanced administration within the organization (Tsai et al., 2022). Machine learning-based AI offers the possibility to improve risk evaluation in cardiovascular disease through its implementation on cardiac nuclear studies (Juarez-Orozco et al., 2022). AI can also calculate event risk at the individual level and has the potential to inform and refine the

application of personalized medicine, providing a more precise and individualized approach to disease risk assessment (Goto & McGuire, 2022). In conclusion, the integration of AI in predicting disease risk offers numerous advantages, including enhanced accuracy, timely intervention, reduced workload for healthcare professionals, and the potential for more precise and individualized risk assessment.

Artificial intelligence (AI) has become increasingly essential in healthcare due to its ability to handle and analyze large volumes of complex medical data quickly and efficiently. AI can identify complex relationships between multiple risk factors and diseases, even when those relationships are nonlinear or interactive, providing more accurate and detailed predictions of disease risk at an individual level (Tsai et al., 2022). The application of AI to disease classification has shown great promise towards increased utility and diagnostic accuracy for medical imaging (Yim et al., 2020). Furthermore, AI has the potential to improve the quality and efficiency of patient assessment and diagnosis in healthcare settings (Nagam, 2023). Additionally, AI models applied to 12-lead ECG waveforms can predict atrial fibrillation, a heritable and morbid arrhythmia (Wang, 2023). The use of predictive analytics via AI and machine learning could enhance the ability to identify clinically significant patterns, including those for infectious diseases (Tran et al., 2021). AI-enabled analysis of 12-lead electrocardiograms may facilitate efficient estimation of incident atrial fibrillation risk (Khurshid et al., 2022). Moreover, AI, including machine learning techniques, has been used for developing prediction models and risk stratification in emergency department patients with chest pain (Zhang et al., 2020).

3.2.2. Challenges and Limitations Still Faced in Disease Risk Prediction

The challenges and limitations in disease risk prediction are multifaceted and encompass various aspects such as model accuracy, data interpretation, and clinical applicability. Machine learning and genetic predisposition are two primary approaches for disease risk prediction (D et al., 2019). However, the application of Polygenic Risk Scores (PRS) as a tool for predicting an individual's disease susceptibility in a clinical setting is challenging because PRS typically provide a relative measure of risk evaluated at the level of a group of people but not at an individual level (Sun et al., 2021). This limitation is further compounded by the potential loss of information resulting from binning subjects into strata based on predicted risk, which is a simple yet limiting aspect of implementation (Austin et al., 2020). Moreover, the prediction of heart disease risk factors using clinical and statistical approaches has attracted significant attention due to the complexity of the process (Houssein et al., 2023).

In the context of specific diseases, the challenges persist. For instance, in the case of diverticulitis, clinical, radiologic, and endoscopic risk prediction tools have been proposed and studied but have not been effectively adopted (Roo et al., 2022). Similarly, in the case of Crohn's disease, patients have more than double the risk of Non-Alcoholic Fatty Liver Disease (NAFLD) compared with the general population after considering traditional risk factors (Hong et al., 2022). This highlights the complexity of disease interrelationships and the need for comprehensive risk assessment models that consider the complex mechanisms of disease development and comorbidity (Wang et al., 2019).

Furthermore, the prediction of the severity of COVID-19-infected patients using machine learning techniques is a challenging problem, emphasizing the need for robust and accurate predictive models in the face of evolving diseases (Alotaibi et al., 2021). Additionally, the prognostic performance of CHA₂DS₂-VASc scores in predicting in-hospital mortality in COVID-19 cases is a critical area of research due to the strong association of its components with an increased risk of mortality in COVID-19 cases Çiçek et al. (2021). In conclusion, disease risk prediction faces challenges and limitations related to the accuracy and applicability of predictive models, the interpretation of data, and the complexity of disease interrelationships. Overcoming these challenges requires a comprehensive understanding of the multifaceted

nature of disease risk prediction and the development of robust, individualized risk prediction models that consider the complex mechanisms of disease development and comorbidity.

The potential of artificial intelligence (AI) in disease risk prediction is substantial, but several challenges and limitations need to be addressed for effective and ethical implementation. One of the primary challenges is the reliance on the quality of available medical data. Medical data is often incomplete, unstructured, or inconsistent, which can hinder the performance of AI models and lead to inaccurate predictions (Pal et al., 2020; Khan et al., 2023; Allam et al., 2021). Additionally, the interpretation of complex AI models poses difficulties for healthcare practitioners without a background in computer science or statistics, potentially impeding the adoption of AI prediction systems in clinical settings (Brady & Neri, 2020; Huang et al., 2023; Ursin et al., 2021). Moreover, ethical considerations, including privacy, data security, and compliance with regulations, are crucial in the use of medical data for predictive purposes (Jaremko et al., 2019; Sethi et al., 2022; Juarez-Orozco et al., 2022).

The literature highlights the potential of AI in predicting disease risk, particularly in infectious diseases and cardiology (Khan et al., 2023; Barbieri, 2024). However, the limitations of existing severity scores and the need for new approaches in predicting outcomes for critically ill patients underscore the importance of addressing these challenges. Furthermore, the ethical implications of AI in disease prediction, especially in pre-symptomatic testing, require careful consideration to avoid potential harm (Sethi et al., 2022; Huang et al., 2023).

In addressing these challenges, it is essential to develop AI frameworks that can effectively utilize incomplete and unstructured medical data while ensuring interpretability for healthcare practitioners. Additionally, attention to privacy and ethical issues is crucial in the design and implementation of AI prediction systems. By addressing these challenges and limitations, AI has the potential to significantly improve disease risk prediction and patient outcomes.

3.3. Disease Prevention with Artificial Intelligence

3.3.1. Prevention Strategies and Models Used with AI

Prevention strategies and models using artificial intelligence (AI) have gained significant attention in various fields, including medicine and public health. developed and validated machine learning-based models for predicting adolescent idiopathic scoliosis (AIS) (Zheng et al., 2023). Their study focused on establishing a prediction model based on machine learning algorithms to improve prediction accuracy and provide targeted prevention strategies for AIS. emphasized the importance of public health strategies targeting Asian Indians (AIs) for the prevention and clinical treatment of conditions such as atherosclerosis and diabetes mellitus (Nair et al., 2022). They highlighted the need for prevention strategies that focus on both conditions jointly, especially in specific demographic groups. Additionally, discussed the future of AI in sports medicine and return to play, emphasizing the potential of AI models in treatment planning and providing personalized risk profiles for prevention strategies (Desai, 2024).

Furthermore, designed a policy model to compare the effectiveness of AI-based screening with in-office clinical exams for preventing vision loss from diabetes, highlighting the potential of AI in preventive care (Channa et al., 2023). developed a multivariate prediction model for forecasting acute ischemic stroke, emphasizing the importance of identifying risk factors for AIS to determine effective preventive measures and treatment suggestions (Yang et al., 2022). These references collectively underscore the potential of AI in developing predictive models and preventive strategies for various health conditions.

In the context of public health, emphasized the need for multilevel strategies for communicating information on suicide risk and prevention to American Indian and Alaska Native adolescents and young adults (Mpofu et al., 2022). This highlights the importance of community and multilevel strategies in suicide prevention for specific populations. Additionally, discussed preventive measures and strategies, including vaccination and national surveillance,

for controlling avian influenza in South Korea, demonstrating the application of AI in disease prevention and control (Sagong et al., 2023). Overall, the references provide insights into the development and application of AI-based models for preventive strategies in various domains, including medicine, public health, and disease control.

Artificial intelligence (AI) has emerged as a transformative tool in disease prevention and management. In battling infectious diseases, AI has shown a transformative role by enabling innovative strategies for disease prevention and control (Li, 2024). Furthermore, in the context of hypertension management, AI has been recognized as a promising tool for reducing the global burden of hypertension and advancing precision medicine related to cardiovascular diseases, including hypertension (Visco et al., 2023). Additionally, in the field of cleft care, there is active interest and immense potential for the use of AI to aid in decisions regarding diagnosis, treatment, and prediction, indicating its applicability in diverse medical domains (Dhillon et al., 2021). Moreover, the use of AI in the collective analysis of a massive number of genome sequences has become increasingly important, particularly in genetics and related fields, where AI is suitable for big data analysis (Ikemura et al., 2021). Furthermore, in geriatric clinical care, AI holds promises to offer better prevention, diagnosis, and treatment for chronic diseases, highlighting its potential in addressing healthcare challenges related to aging populations (Choudhury et al., 2020). Lastly, AI has been identified as a valuable tool in clinical and genomic diagnostics, enabling computer systems to perform tasks that typically require human intelligence, thereby revolutionizing disease diagnosis and management (Dias & Torkamani, 2019).

These references collectively demonstrate the wide-ranging applications of AI in disease prevention, from infectious diseases to chronic conditions, and its potential to revolutionize healthcare by providing innovative and effective strategies for disease management and prevention.

3.3.2. Success Rate of AI Implementation in Disease Prevention

The success rate of artificial intelligence (AI) implementation in disease prevention is a topic of growing interest and importance in the field of healthcare. While AI has shown potential applications across various domains of medicine (Kelly et al., 2019), there are challenges and barriers to its effective implementation (Borkowski, 2022). Previous research has indicated that there is some reluctance among patients to fully embrace AI in disease-related interventions (Jin et al., 2022). However, the integration of AI technologies has the potential to augment patient education, streamline disease prevention initiatives, and enhance health literacy (Paliwal et al., 2023). Furthermore, AI-based systems have achieved significant success in healthcare and have the potential to reshape medicine in the years ahead (Rajpurkar et al., 2022). Successful AI implementation in healthcare requires addressing barriers and challenges, such as regulatory oversight, safety, and transparency (Mooghali, 2023; Benjamins et al., 2020). Additionally, the use of AI algorithms can help healthcare providers diagnose diseases accurately and quickly, potentially improving patient outcomes (Saeed et al., 2023). Moreover, the successful implementation of AI in disease prevention requires the identification and implementation of effective programs tailored to specific at-risk populations (Mohatt et al., 2023). Overall, the successful deployment of AI models in disease prevention is crucial, especially in rapidly evolving pandemics, and requires addressing challenges and maximizing the potential of AI through international cooperation (Bullock et al., 2020; Hu et al., 2020).

The successful implementation of AI approaches in disease prevention is contingent upon various factors, including data availability, integration with existing health systems, stakeholder support, and resource availability (Ranson et al., 2023). AI methods have shown promise in neuroimaging for diagnostic classification, although challenges related to validation and translation persist (Ranson et al., 2023). Additionally, AI has the potential to assist

physicians in clinical tasks, from disease identification to lesion segmentation (Jin et al., 2022). In the context of disease prediction, AI approaches such as logistic regression, decision trees, and neural networks have been employed, showcasing their potential in disease prevention (Wong et al., 2021). However, ethical concerns regarding the use of AI in clinical decision-making and the privacy of medical data remain significant challenges (Khan et al., 2022). Furthermore, the evaluation of AI models for disease prevention is crucial to assess their effectiveness, efficiency, and long-term impact (Ranson et al., 2023).

The use of AI in disease prevention has been particularly highlighted in the context of the COVID-19 pandemic, with AI approaches being suggested to provide solutions for maximizing safety and preventing the spread of the virus (Adly et al., 2020). Early diagnosis and treatment facilitated by AI have been emphasized as crucial in addressing the pandemic (Vaishya et al., 2020). Moreover, AI has been leveraged in diverse medical domains, such as liver tumor diagnosis and bowel preparation evaluation before colonoscopy, demonstrating its potential in various healthcare applications (Nishida et al., 2022; Lu et al., 2022). However, the ethical implications of AI in healthcare, including privacy preservation and ethical decision-making, have garnered increasing attention (Pflanzer et al., 2022; Zhou & Nabus, 2023). In conclusion, while AI holds significant potential in disease prevention, its successful implementation is contingent upon addressing challenges related to data quality, ethical considerations, and the thorough evaluation of its impact. The integration of AI into healthcare systems necessitates a holistic and sustainable approach that considers the multifaceted challenges and opportunities associated with AI in disease prevention.

3.3. Discussion of the Implications of the Findings for Clinical Practice and Health Policy

3.3.1. AI Contribution in Increasing the Effectiveness of Disease Prevention

Artificial Intelligence (AI) has indeed made significant contributions to disease prevention and control, particularly in infectious diseases and cardiovascular healthcare. AI technology has been instrumental in digitizing the process of remote data collection and disease monitoring, providing real-time data in the patient's environment (Gill et al., 2023). Furthermore, AI has played a crucial role in predicting the epidemic trend of COVID-19 and in reducing the eventual COVID-19 epidemic size through the implementation of control measures (Yang et al., 2020). The combination of AI technology and 5G network technology has been shown to effectively contribute to the reduction of cross-infection and treatment pressure, thereby improving treatment efficiency (龚玲, 2022). Additionally, AI applications have presented opportunities for the future of healthcare, particularly in responding to the complexities of COVID-19 (Jiang et al., 2020). Moreover, the integration of existing IoT and AI technologies can enhance disease detection, monitoring, and quarantine, thus contributing to disease control systems (Sim & Cho, 2021).

In the realm of cardiovascular healthcare, AI has been leveraged in cardiovascular imaging, presenting promising applications that potentially add value to patient care (Dey et al., 2019). Furthermore, AI has been utilized to address disparities in secondary prevention of atherosclerotic heart disease, particularly in specific populations such as Northern Plains American Indians (Kruger et al., 2019). The role of AI in managing adrenal insufficiency, a group of rare diseases, has also been explored, highlighting its potential in addressing rare disease management (Ali & Beshyah, 2021). In conclusion, AI has made significant contributions to disease prevention and control, particularly in infectious diseases and cardiovascular healthcare. Its applications in digitizing data collection, predicting disease trends, and enhancing disease detection and monitoring have been pivotal in improving disease prevention efforts.

Artificial intelligence (AI) has emerged as a powerful tool in disease prevention, offering the capability to analyze large and complex medical data to identify patterns useful in disease prevention efforts (Matheny et al., 2020). By applying AI to the analysis of population

health data, higher risk groups can be identified, disease progression can be predicted more accurately, and more targeted interventions can be designed (Matheny et al., 2020). Studies have shown that the application of AI in disease prevention strategies can improve early detection, reduce disease incidence rates, and optimize the allocation of health resources (Matheny et al., 2020). AI has been widely used in various medical fields, including dentistry, radiology, and neurology, demonstrating its potential to revolutionize healthcare and disease prevention (Hwang et al., 2019; Gokdeniz & Kamburoğlu, 2022; Marasini et al., 2022).

However, the use of AI in healthcare also raises concerns about bias and equity, as there have been instances of racial and gender bias in AI-based technologies (Parikh et al., 2019). Additionally, the potential liability for physicians using AI in medical practice, especially in forms that rely on machine learning, has been a subject of discussion (Price et al., 2019). It is crucial to address these issues to ensure that AI is used ethically and responsibly in disease prevention efforts.

Furthermore, the COVID-19 pandemic has highlighted the need for more complete case report data and timely, culturally responsive, and evidence-based public health efforts that leverage the strengths of communities, including the use of AI in disease prevention and control (Hatcher et al., 2020). AI has the potential to strengthen global health systems and mitigate future health crises, making it a global health imperative (Gulumbe et al., 2023). In conclusion, AI has the potential to significantly improve disease prevention efforts by leveraging its ability to analyze large and complex medical data, identify patterns, and optimize the allocation of health resources. However, it is essential to address concerns regarding bias, equity, and liability to ensure the ethical and responsible use of AI in healthcare and disease prevention.

3.3.2. Challenges and Ethical Impact of Using AI in Disease Prevention

The use of artificial intelligence (AI) in disease prevention presents various challenges and ethical implications. These include issues of privacy, encoded bias, integration into clinical workflows, and ethical considerations (Rowe & Lester, 2020). The impact of AI on human society raises concerns about existential risks, privacy, bias, and the development of AI systems meeting ethical standards (Zhang et al., 2022). Furthermore, the ethical challenges posed by AI in terms of transparency and the implementation of ethics are highlighted (Huriye, 2023). Challenges in implementing ethics in AI and future perspectives are also pointed out (Huang et al., 2023). The awareness of the social impact and ethical implications of AI has increased within various stakeholders, including academia, government, civil society, and industry (Kazim & Koshiyama, 2020).

In the context of disease prevention, challenges include the need to develop regulations and guidelines for the use of AI solutions in healthcare (Saeed et al., 2023). AI has been proposed to support the response to pandemics, including disease forecasting, surveillance, and antiviral drug discovery (Hu et al., 2020). The importance of ethical considerations for researchers and students when using AI, as well as the need for educators to prepare for the increasing prevalence of AI in academia and industry, is emphasized (Cain, 2023). The rapid progress in AI technologies has brought increasing attention to their potential impacts on society, with ethically questionable consequences (Tidjon, 2022).

In the realm of infectious disease prevention and control, AI technology has ushered in a revolutionary era, making transformative contributions (Li, 2024). While ethical concerns regarding AI have received considerable attention, the epistemological dimension has been largely neglected (Chavanayarn, 2023). The integration of AI with the health field presents challenges in terms of data and technology, highlighting the need for regulations and guidelines (Guo, 2022). AI has the potential to impact future patient care and address challenges, reducing the workload of healthcare professionals (Vaishya et al., 2020).

As the demand for ethical AI systems increases, the number of unethical uses of AI

accelerates, necessitating the resolution of the social dilemma in AI development (Strümke et al., 2021). AI-based applications have the potential to impact clinical management in the context of the COVID-19 pandemic, but several challenges hinder more widespread implementation (Khemasuwan & Colt, 2021). Exciting progress has been made in the application of AI in disease diagnosis, especially in the medical and health fields (Dong et al., 2021). The challenges and opportunities for utilizing AI approaches in dementia research are highlighted, emphasizing the potential for AI to contribute to prevention and treatment (Ranson et al., 2023).

In the context of individualized medicine applications, the future potential of AI is discussed, along with the challenges, limitations, and biases that must be carefully addressed for successful deployment (Dias & Torkamani, 2019). The ethical implications of AI for meaningful work and the ways in which AI deployment may support or diminish opportunities for meaningful work are under-explored (Bankins & Formosa, 2023). Concerns about the ethical and medico-legal impact of health AI research have been raised, emphasizing the need for a clear understanding of how to quantify benefit and ensure patient safety (Challen et al., 2019).

The role of artificial intelligence (AI) in disease prevention has garnered significant attention in the medical and scientific communities. AI has demonstrated the potential to enhance disease prevention strategies through its ability to analyze large and complex medical data, enabling the identification of patterns useful in disease prevention efforts (N., 2021). By applying AI to the analysis of population health data, higher risk groups can be identified, disease progression can be predicted more accurately, and more targeted interventions can be designed (Ciccarelli et al., 2023). Studies have shown that the application of AI in disease prevention strategies can improve early detection, reduce disease incidence rates, and optimize the allocation of health resources (Mijwil et al., 2022).

However, the use of AI in disease prevention also raises ethical challenges that need to be carefully considered. One of the main challenges is protecting the privacy and security of patient data, as the use of sensitive medical data in AI analysis may pose a risk of data leakage or misuse of personal information (Tzachor et al., 2020). Additionally, attention is needed to ensure fairness and diversity in the development of AI models, as reliance on medical data that may not reflect population diversity can result in biased and unfair AI models, potentially increasing disparities in health care (Khan et al., 2023). Furthermore, careful consideration is needed regarding how AI prediction results are used in clinical decision making, including responsibility and accountability in the use of the technology (Pflanzer et al., 2022). By addressing these ethical challenges, the development and application of AI in disease prevention can be more sustainable and aligned with fundamental ethical and human values.

4. Conclusion

In a systematic review of the literature conducted from 2019 to 2024, an increase in the use of artificial intelligence (AI) in disease risk prediction and disease prevention was seen. Various studies have demonstrated the potential of AI in improving the effectiveness of disease risk prediction using various AI methods such as machine learning algorithms, artificial neural networks, and decision trees. The results show that AI is able to identify complex patterns in health data to more accurately predict disease risk, provide timely interventions, and improve clinical management of patients. Additionally, the integration of AI with medical technologies such as medical image scanning has promised to improve disease diagnosis and help in the prevention of diseases such as cancer and cardiovascular diseases.

However, the use of AI in disease risk prediction is also faced with various challenges and ethical impacts that need to be overcome. Key challenges include limited available health data, complexity of AI models, complex interpretation of results, and privacy and ethical concerns. In addition, it is necessary to consider the ethical impact of using AI in clinical

decision making, including considerations about bias and fairness, as well as responsibility and accountability in the use of this technology.

Nonetheless, by addressing the challenges and paying attention to its ethical implications, the use of AI in disease risk prediction has great potential to increase the effectiveness of disease prevention and improve patient clinical outcomes. A holistic and sustainable approach is needed in the development and implementation of AI models in disease prevention, which considers the complex challenges and opportunities associated with the use of AI in health contexts. Additionally, efforts to address privacy, bias, and ethical concerns should be a priority in integrating AI into healthcare systems to ensure its use is responsible and in line with fundamental ethical and human values.

5. References

The integration of artificial intelligence (AI) in the field of medicine has sparked a revolution, offering the potential to predict, prevent, and cure diseases. AI, through algorithms and predictive models, has shown promise in diagnosing diseases, predicting therapeutic responses, and enabling personalized medicine (Kumar et al., 2022). This has generated enthusiasm in the medical field, as AI has the potential to assist physicians in establishing diagnoses, predicting the risk of diseases, and facilitating drug discovery (Diaconu et al., 2022). Furthermore, AI is driving a transformation in healthcare, enabling a shift towards proactive and personalized medicine, aligning with the concept of P5 medicine – predictive, personalized, preventive, participatory, and precision-focused discipline (Denecke & Baudoin, 2022).

The use of AI in disease diagnosis has been assessed through various strategies such as Logit Boost, Bayesian Network Classifier, Support Vector Machine, and Random Tree Forest, showing potential in identifying conditions like hypertension (Kumar et al., 2022). However, the adoption of AI in the healthcare system and medical education is a rapidly growing area, emphasizing the importance of involving healthcare professionals and educators in the development and implementation of AI-enabled tools in medicine (Iqbal, 2022). Additionally, AI algorithms, including data-driven, image-driven, natural language processing (NLP)-driven, genomics-driven, and multimodality algorithms, have been instrumental in improving disease detection and outcomes (Lim et al., 2022).

While AI presents significant potential, there are also challenges to address. The application of AI in medicine raises concerns regarding bias and clinical safety, as machine learning techniques are increasingly applied to complex problems, allowing computers to make predictions from large amounts of patient data (Challen et al., 2019). Moreover, the implementation of AI in the practice of medicine requires meeting specific requirements, and unlike other medical imaging areas, no histopathology-based AI application has been approved for public reimbursement (Yoshida & Kiyuna, 2021).

In the context of the COVID-19 pandemic, modern technologies, including AI, have been pivotal in disease tracking, prediction outcomes, and computational biology, highlighting the diverse applications of AI in addressing public health crises (Kumar et al., 2020). Furthermore, the understanding of causality within data, facilitated by causal inference, has been identified as a significant component of AI, promoting human understanding of the learning process and model prediction (Ma & Li, 2022).

In conclusion, the integration of AI in medicine holds immense potential for revolutionizing disease diagnosis, prediction, prevention, and personalized medicine. However, it is essential to address challenges such as bias, clinical safety, and regulatory approval to fully harness the benefits of AI in transforming healthcare.

5. References

Abdekhoda, M. and Ranjbaran, F. (2023). Artificial intelligence applications in decision making for disease management.. <https://doi.org/10.21203/rs.3.rs-3110088/v1>

- Ahmad, W., Ghani, N., & Drus, S. (2019). Handling imbalanced class problem of measles infection risk prediction model. *International Journal of Engineering and Advanced Technology*, 9(1), 3431-3435. <https://doi.org/10.35940/ijeat.a2649.109119>
- Ali, K. and Beshyah, S. (2021). Management of adrenal insufficiency: a survey of perceptions and practices of physicians from the middle east and north africa. *Journal of Diabetes and Endocrine Practice*, 04(03), 125-130. https://doi.org/10.4103/jdep.jdep_12_21
- Almansour, N. (2022). Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. *Frontiers in Molecular Biosciences*, 9. <https://doi.org/10.3389/fmolb.2022.836417>
- Al-Shoteri, A. (2022). The role of methods and applications of artificial intelligence tools in the field of medicine to diagnose and discover various diseases. *Journal of Applied Data Sciences*, 3(1), 01-14. <https://doi.org/10.47738/jads.v3i1.48>
- Barbieri, M. (2024). Artificial intelligence for the optimal management of community-acquired pneumonia. *Current Opinion in Pulmonary Medicine*, 30(3), 252-257. <https://doi.org/10.1097/mcp.0000000000001055>
- Beheshti, I., Sone, D., Yao, Z., & Maikusa, N. (2023). Editorial: state-of-the-art artificial intelligence methods in neurodegeneration. *Frontiers in Neurology*, 13. <https://doi.org/10.3389/fneur.2022.1112639>
- Challen, R., Denny, J., Pitt, M., Gompels, L., Edwards, T., & Tsaneva-Atanasova, K. (2019). Artificial intelligence, bias and clinical safety. *BMJ Quality & Safety*, 28(3), 231-237. <https://doi.org/10.1136/bmjqs-2018-008370>
- Chen, P., Chang, D., Wu, T., Wu, M., Wang, W., & Liao, W. (2021). Applications of artificial intelligence in pancreatic and biliary diseases. *Journal of Gastroenterology and Hepatology*, 36(2), 286-294. <https://doi.org/10.1111/jgh.15380>
- Choudhury, A., Renjilian, E., & Asan, O. (2020). Use of machine learning in geriatric clinical care for chronic diseases: a systematic literature review. *Jamia Open*, 3(3), 459-471. <https://doi.org/10.1093/jamiaopen/ooaa034>
- Ciccarelli, M., Giallauria, F., Carrizzo, A., Visco, V., Silverio, A., Cesaro, A., ... & Vecchione, C. (2023). Artificial intelligence in cardiovascular prevention: new ways will open new doors. *Journal of Cardiovascular Medicine*, 24(Supplement 2), e106-e115. <https://doi.org/10.2459/jcm.0000000000001431>
- Denecke, K. and Baudoin, C. (2022). A review of artificial intelligence and robotics in transformed health ecosystems. *Frontiers in Medicine*, 9. <https://doi.org/10.3389/fmed.2022.795957>
- Dey, D., Slomka, P., Leeson, P., Comaniciu, D., Shrestha, S., Sengupta, P., ... & Marwick, T. (2019). Artificial intelligence in cardiovascular imaging. *Journal of the American College of Cardiology*, 73(11), 1317-1335. <https://doi.org/10.1016/j.jacc.2018.12.054>
- Dhillon, H., Chaudhari, P., Dhingra, K., Kuo, R., Sokhi, R., Alam, M., ... & Ahmad, S. (2021). Current applications of artificial intelligence in cleft care: a scoping review. *Frontiers in Medicine*, 8. <https://doi.org/10.3389/fmed.2021.676490>
- Diaconu, A., Cojocaru, F., Gardikiotis, I., Agrigoroaie, L., Furcea, D., Pasat, A., ... & Dodi, G. (2022). Expanding the power of artificial intelligence in preclinical research: an overview. *Iop Conference Series Materials Science and Engineering*, 1254(1), 012036. <https://doi.org/10.1088/1757-899x/1254/1/012036>
- Dias, R. and Torkamani, A. (2019). Artificial intelligence in clinical and genomic diagnostics. *Genome Medicine*, 11(1). <https://doi.org/10.1186/s13073-019-0689-8>
- Gill, S., Karwath, A., Uh, H., Cardoso, V., Gu, Z., Barsky, A., ... & Kotecha, D. (2023). Artificial intelligence to enhance clinical value across the spectrum of cardiovascular healthcare. *European Heart Journal*, 44(9), 713-725. <https://doi.org/10.1093/eurheartj/ehac758>
- Gokdeniz, S. and Kamburoğlu, K. (2022). Artificial intelligence in dentomaxillofacial radiology. *World Journal of Radiology*, 14(3), 55-59. <https://doi.org/10.4329/wjr.v14.i3.55>
- Goto, S. and McGuire, D. (2022). The future role of high-performance computing in

- cardiovascular medicine and science -impact of multi-dimensional data analysis-. *Journal of Atherosclerosis and Thrombosis*, 29(5), 559-562. <https://doi.org/10.5551/jat.rv17062>
- Gulumbe, B., Yusuf, Z., & Hashim, A. (2023). Harnessing artificial intelligence in the post-covid-19 era: a global health imperative. *Tropical Doctor*, 53(4), 414-415. <https://doi.org/10.1177/00494755231181155>
- Hatcher, S., Agnew-Brune, C., Anderson, M., Zambrano, L., Rose, C., Jim, M., ... & McCollum, J. (2020). Covid-19 among american indian and alaska native persons — 23 states, january 31–july 3, 2020. *MMWR Morbidity and Mortality Weekly Report*, 69(34), 1166-1169. <https://doi.org/10.15585/mmwr.mm6934e1>
- Hwang, J., Jung, Y., Cho, B., & Heo, M. (2019). An overview of deep learning in the field of dentistry. *Imaging Science in Dentistry*, 49(1), 1. <https://doi.org/10.5624/isd.2019.49.1.1>
- Ikemura, T., Iwasaki, Y., Wada, K., Wada, Y., & T, A. (2021). Unsupervised explainable ai for the collective analysis of a massive number of genome sequences: various examples from the small genome of pandemic sars-cov-2 to the human genome.. <https://doi.org/10.1101/2021.05.23.445371>
- Iqbal, S. (2022). Are medical educators primed to adopt artificial intelligence in healthcare system and medical education?. *Health Professions Educator Journal*, 5(1), 7-8. <https://doi.org/10.53708/hpej.v5i1.1707>
- Jiang, X., Coffee, M., Bari, A., Wang, J., Jiang, X., Huang, J., ... & Huang, Y. (2020). Towards an artificial intelligence framework for data-driven prediction of coronavirus clinical severity. *Computers Materials & Continua*, 62(3), 537-551. <https://doi.org/10.32604/cmc.2020.010691>
- Johnson, K., Wei, W., Weeraratne, D., Frisse, M., Misulis, K., Rhee, K., ... & Snowden, J. (2020). Precision medicine, ai, and the future of personalized health care. *Clinical and Translational Science*, 14(1), 86-93. <https://doi.org/10.1111/cts.12884>
- Juarez-Orozco, L., Klén, R., Niemi, M., Ruijsink, B., Daquarti, G., Es, R., ... & Knuuti, J. (2022). Artificial intelligence to improve risk prediction with nuclear cardiac studies. *Current Cardiology Reports*, 24(4), 307-316. <https://doi.org/10.1007/s11886-022-01649-w>
- Khan, A., Akbar, M., Fahmideh, M., Liang, P., Waseem, M., Ahmad, A., ... & Abrahamsson, P. (2023). Ai ethics: an empirical study on the views of practitioners and lawmakers. *Ieee Transactions on Computational Social Systems*, 10(6), 2971-2984. <https://doi.org/10.1109/tcss.2023.3251729>
- Khurshid, S., Friedman, S., Reeder, C., Achille, P., Diamant, N., Singh, P., ... & Lubitz, S. (2022). Ecg-based deep learning and clinical risk factors to predict atrial fibrillation. *Circulation*, 145(2), 122-133. <https://doi.org/10.1161/circulationaha.121.057480>
- Kruger, H., Zumwalt, C., Guenther, R., Jansen, R., Warne, D., & Dyke, C. (2019). Disparities in secondary prevention of atherosclerotic heart disease after coronary artery bypass grafting in northern plains american indians. *Health Equity*, 3(1), 520-526. <https://doi.org/10.1089/heq.2019.0030>
- Kumar, A., Gupta, P., & Srivastava, A. (2020). A review of modern technologies for tackling covid-19 pandemic. *Diabetes & Metabolic Syndrome Clinical Research & Reviews*, 14(4), 569-573. <https://doi.org/10.1016/j.dsx.2020.05.008>
- Kumar, Y., Koul, A., Singla, R., & Ijaz, M. (2022). Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda. *Journal of Ambient Intelligence and Humanized Computing*, 14(7), 8459-8486. <https://doi.org/10.1007/s12652-021-03612-z>
- Li, C. (2024). Artificial intelligence in battling infectious diseases: a transformative role. *Journal of Medical Virology*, 96(1). <https://doi.org/10.1002/jmv.29355>
- Li, S. and Chong-Wen, W. (2022). Predictors of rapid eye movement sleep behavior disorder in patients with parkinson's disease based on random forest and decision tree. *Plos One*, 17(6), e0269392. <https://doi.org/10.1371/journal.pone.0269392>
- Lim, J., Hong, M., Lam, S., Zhang, Z., Teo, Z., Liu, Y., ... & Ting, D. (2022). Novel technical

- and privacy-preserving technology for artificial intelligence in ophthalmology. *Current Opinion in Ophthalmology*, 33(3), 174-187. <https://doi.org/10.1097/icu.0000000000000846>
- Liu, P. (2024). Machine learning versus multivariate logistic regression for predicting severe covid-19 in hospitalized children with omicron variant infection. *Journal of Medical Virology*, 96(2). <https://doi.org/10.1002/jmv.29447>
- Ma, J. and Li, J. (2022). Learning causality with graphs. *Ai Magazine*, 43(4), 365-375. <https://doi.org/10.1002/aaai.12070>
- Mahadevan, S., Wojtuszczyński, A., Favre, L., Boughorbel, S., Shan, J., Letaief, K., ... & Chouchane, L. (2020). Precision medicine in the era of artificial intelligence: implications in chronic disease management. *Journal of Translational Medicine*, 18(1). <https://doi.org/10.1186/s12967-020-02658-5>
- Marasini, A., Shrestha, A., Phuyal, S., Zaidat, O., & Kalia, J. (2022). Role of artificial intelligence in unruptured intracranial aneurysm: an overview. *Frontiers in Neurology*, 13. <https://doi.org/10.3389/fneur.2022.784326>
- Mascarenhas, A., Silva, M., & Barra, R. (2021). Artificial intelligence and nuclear cardiology - a current overview / inteligência artificial e cardiologia nuclear – um panorama atual. *Brazilian Journal of Health Review*, 4(2), 7678-7682. <https://doi.org/10.34119/bjhrv4n2-304>
- Matheny, M., Whicher, D., & Israni, S. (2020). Artificial intelligence in health care. *Jama*, 323(6), 509. <https://doi.org/10.1001/jama.2019.21579>
- Mijwil, M., Aggarwal, K., Doshi, R., Hiran, K., & Sundaravadivazhagan, B. (2022). Deep learning techniques for covid-19 detection based on chest x-ray and ct-scan images: a short review and future perspective. *Asian Journal of Applied Sciences*, 10(3). <https://doi.org/10.24203/ajas.v10i3.6998>
- Mirkin, S. and Albeni, B. (2023). Should artificial intelligence be used in conjunction with neuroimaging in the diagnosis of alzheimer's disease?. *Frontiers in Aging Neuroscience*, 15. <https://doi.org/10.3389/fnagi.2023.1094233>
- Mohan, S., Thirumalai, C., & Srivastava, G. (2019). Effective heart disease prediction using hybrid machine learning techniques. *Ieee Access*, 7, 81542-81554. <https://doi.org/10.1109/access.2019.2923707>
- N., M. (2021). Applications of artificial intelligence in battling against covid-19: a literature review. *Chaos Solitons & Fractals*, 142, 110338. <https://doi.org/10.1016/j.chaos.2020.110338>
- Nagam, V. (2023). Diagnostic medical artificial intelligence: futuristic prospects for implementation in healthcare settings. *Frontiers in Artificial Intelligence*, 6. <https://doi.org/10.3389/frai.2023.1169244>
- Parikh, R., Teeple, S., & Navathe, A. (2019). Addressing bias in artificial intelligence in health care. *Jama*, 322(24), 2377. <https://doi.org/10.1001/jama.2019.18058>
- Pflanzer, M., Traylor, Z., Lyons, J., Dubljević, V., & Nam, C. (2022). Ethics in human-ai teaming: principles and perspectives. *Ai and Ethics*, 3(3), 917-935. <https://doi.org/10.1007/s43681-022-00214-z>
- Price, W., Gerke, S., & Cohen, I. (2019). Potential liability for physicians using artificial intelligence. *Jama*, 322(18), 1765. <https://doi.org/10.1001/jama.2019.15064>
- Sahu, D. and Kumar, S. (2022). Human disease prediction using machine learning classification algorithms. *International Journal of Engineering Technology and Management Sciences*, 6(6), 7-13. <https://doi.org/10.46647/ijetms.2022.v06i06.002>
- Sahu, D. and Kumar, S. (2022). Predictive analysis for the detection of human diseases cvd, ckd, dm based on supervised and ensemble machine learning classification algorithms. *International Journal of Engineering Technology and Management Sciences*, 6(6), 1-6. <https://doi.org/10.46647/ijetms.2022.v06i06.001>
- Sarraj, A., Bruemmer, D., Iterson, E., Cho, L., Rodríguez, F., & Laffin, L. (2023). Appropriateness of cardiovascular disease prevention recommendations obtained from a popular online chat-based artificial intelligence model. *Jama*, 329(10), 842.

- <https://doi.org/10.1001/jama.2023.1044>
- Siddiq, M. (2022). Use of machine to predict patient developing a disease or condition for early diagnose. *International Journal of Multidisciplinary Sciences and Arts*, 1(1). <https://doi.org/10.47709/ijmdsa.v1i1.2271>
- Sim, S. and Cho, M. (2021). Convergence model of ai and iot for virus disease control system. *Personal and Ubiquitous Computing*, 27(3), 1209-1219. <https://doi.org/10.1007/s00779-021-01577-6>
- Stafford, I., Kellermann, M., Mossotto, E., Beattie, R., MacArthur, B., & Ennis, S. (2020). A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases. *NPJ Digital Medicine*, 3(1). <https://doi.org/10.1038/s41746-020-0229-3>
- Tran, N., Albahra, S., May, L., Waldman, S., Crabtree, S., Bainbridge, S., ... & Rashidi, H. (2021). Evolving applications of artificial intelligence and machine learning in infectious diseases testing. *Clinical Chemistry*, 68(1), 125-133. <https://doi.org/10.1093/clinchem/hvab239>
- Tran, N., Kretsch, C., LaValley, C., & Rashidi, H. (2023). Machine learning and artificial intelligence for the diagnosis of infectious diseases in immunocompromised patients. *Current Opinion in Infectious Diseases*, 36(4), 235-242. <https://doi.org/10.1097/qco.0000000000000935>
- Tsai, W., Lin, H., Hsu, C., Ma, Y., Chen, C., Huang, C., ... & Chen, C. (2022). Design and implementation of a comprehensive ai dashboard for real-time prediction of adverse prognosis of ed patients. *Healthcare*, 10(8), 1498. <https://doi.org/10.3390/healthcare10081498>
- Tsai, W., Lin, H., Hsu, C., Ma, Y., Chen, C., Huang, C., ... & Chen, C. (2022). Design and implementation of a comprehensive ai dashboard for real-time prediction of adverse prognosis of ed patients. *Healthcare*, 10(8), 1498. <https://doi.org/10.3390/healthcare10081498>
- Tzachor, A., Whittlestone, J., Sundaram, L., & hÉigearthaigh, S. (2020). Artificial intelligence in a crisis needs ethics with urgency. *Nature Machine Intelligence*, 2(7), 365-366. <https://doi.org/10.1038/s42256-020-0195-0>
- Vaishya, R., Javaid, M., Khan, I., & Haleem, A. (2020). Artificial intelligence (ai) applications for covid-19 pandemic. *Diabetes & Metabolic Syndrome Clinical Research & Reviews*, 14(4), 337-339. <https://doi.org/10.1016/j.dsx.2020.04.012>
- Visco, V., Izzo, C., Mancusi, C., Rispoli, A., Tedeschi, M., Virtuoso, N., ... & Ciccarelli, M. (2023). Artificial intelligence in hypertension management: an ace up your sleeve. *Journal of Cardiovascular Development and Disease*, 10(2), 74. <https://doi.org/10.3390/jcdd10020074>
- Wang, X. (2023). Genetic susceptibility to atrial fibrillation identified via deep learning of 12-lead electrocardiograms. *Circulation Genomic and Precision Medicine*, 16(4), 340-349. <https://doi.org/10.1161/circgen.122.003808>
- Wong, G., Yuen, P., Andy, J., Chan, A., Leung, H., & Wong, V. (2021). Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis. *Journal of Gastroenterology and Hepatology*, 36(3), 543-550. <https://doi.org/10.1111/jgh.15385>
- Yang, Z., Zeng, Z., Wang, K., Wong, S., Liang, W., Zanin, M., ... & He, J. (2020). Modified seir and ai prediction of the epidemics trend of covid-19 in china under public health interventions. *Journal of Thoracic Disease*, 12(3), 165-174. <https://doi.org/10.21037/jtd.2020.02.64>
- Yim, J., Chopra, R., Spitz, T., Winkens, J., Obika, A., Kelly, C., ... & Fauw, J. (2020). Predicting conversion to wet age-related macular degeneration using deep learning. *Nature Medicine*, 26(6), 892-899. <https://doi.org/10.1038/s41591-020-0867-7>
- Yin, J., Ngiam, K., & Teo, H. (2021). Role of artificial intelligence applications in real-life clinical practice: systematic review. *Journal of Medical Internet Research*, 23(4), e25759. <https://doi.org/10.2196/25759>
- Yoshida, H. and Kiyuna, T. (2021). Requirements for implementation of artificial intelligence in

- the practice of gastrointestinal pathology. *World Journal of Gastroenterology*, 27(21), 2818-2833. <https://doi.org/10.3748/wjg.v27.i21.2818>
- Zhang, P., Hsu, C., Kao, Y., Kuo, Y., Hsu, S., Liu, T., ... & Huang, C. (2020). Real-time ai prediction for major adverse cardiac events in emergency department patients with chest pain. *Scandinavian Journal of Trauma Resuscitation and Emergency Medicine*, 28(1). <https://doi.org/10.1186/s13049-020-00786-x>
- Zhang, Z., Li, J., He, T., & Ding, J. (2020). Bioinformatics identified 17 immune genes as prognostic biomarkers for breast cancer: application study based on artificial intelligence algorithms. *Frontiers in Oncology*, 10. <https://doi.org/10.3389/fonc.2020.00330>